BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22854670)

  • 1. Overview of the cancer vaccine field: are we moving forward?
    Kudrin A; Hanna MG
    Hum Vaccin Immunother; 2012 Aug; 8(8):1135-40. PubMed ID: 22854670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer vaccines: what do we need to measure in clinical trials?
    Kudrin A
    Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer.
    Berzofsky JA; Wood LV; Terabe M
    Expert Rev Vaccines; 2013 Oct; 12(10):1115-8. PubMed ID: 24124874
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer.
    Hanna MG
    Hum Vaccin Immunother; 2012 Aug; 8(8):1156-60. PubMed ID: 22854664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized cancer neoantigen vaccines come of age.
    Chu Y; Liu Q; Wei J; Liu B
    Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer vaccines in the new era of cancer immunotherapy.
    Knutson KL; Mittendorf EA
    Vaccine; 2015 Dec; 33(51):7376. PubMed ID: 26432907
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic cancer vaccines: a long and winding road to success.
    Baxevanis CN; Papamichail M; Perez SA
    Expert Rev Vaccines; 2014 Jan; 13(1):131-44. PubMed ID: 24224539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in the development of an autologous heat shock protein based anti-tumor vaccine.
    Reitsma DJ; Combest AJ
    Hum Vaccin Immunother; 2012 Aug; 8(8):1152-5. PubMed ID: 22854658
    [No Abstract]   [Full Text] [Related]  

  • 9. New developments in cancer vaccines.
    Buonaguro L; Aurisicchio L; Buonaguro FM; Ciliberto G
    Expert Rev Vaccines; 2013 Oct; 12(10):1109-10. PubMed ID: 24124872
    [No Abstract]   [Full Text] [Related]  

  • 10. A New Generation of Vaccines in the Age of Immunotherapy.
    Addeo A; Friedlaender A; Giovannetti E; Russo A; de Miguel-Perez D; Arrieta O; Cardona AF; Rolfo C
    Curr Oncol Rep; 2021 Nov; 23(12):137. PubMed ID: 34735649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer neoantigen: Boosting immunotherapy.
    Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
    Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer vaccines: are we there yet?
    Hanna MG
    Hum Vaccin Immunother; 2012 Aug; 8(8):1161-5. PubMed ID: 22854657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systems vaccinology for cancer vaccine development.
    Petrizzo A; Tagliamonte M; Tornesello M; Buonaguro FM; Buonaguro L
    Expert Rev Vaccines; 2014 Jun; 13(6):711-9. PubMed ID: 24766452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for the future of prostate cancer vaccines.
    Madan RA; Gulley JL
    Expert Rev Vaccines; 2016; 15(3):271-4. PubMed ID: 26560494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.
    Gjerstorff MF; Burns J; Ditzel HJ
    Expert Opin Biol Ther; 2010 Jul; 10(7):1061-75. PubMed ID: 20420535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer vaccine development represents a particularly interesting and active field.
    Ellis R; Riedmann EM
    Hum Vaccin Immunother; 2012 Aug; 8(8):1013. PubMed ID: 22914448
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic.
    Singh R; Wallecha A
    Hum Vaccin; 2011 May; 7(5):497-505. PubMed ID: 21422819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of cancer vaccines: considerations for development.
    Kudrin A
    Hum Vaccin Immunother; 2012 Sep; 8(9):1335-53. PubMed ID: 22894970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.